Aura Biosciences prices $260M public offering to fund clinical programs and repurchase shares

Aura Biosciences announced a $260.3 million public offering of common stock and pre-funded warrants priced at $6.00 and $5.99999 respectively. The company plans to use $205.1 million of the proceeds to advance clinical programs, including late-stage development for early choroidal melanoma, and for general corporate purposes. Additionally, Aura intends to repurchase nearly 6.9 million shares from a major stockholder at $5.64 per share. The offering is expected to close around May 5, 2026, subject to customary conditions. This capital raise supports Aura's mission to develop precision therapies for solid tumors while preserving organ function.